MSFP
ARTV

Mark Sheptoff Financial Planning’s Artiva Biotherapeutics ARTV Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.24K Hold
400
– – ﹤0.01% 450
2025
Q4 		$1.72K Hold
400
– – ﹤0.01% 480
2025
Q3 		$1.15K Hold
400
– – ﹤0.01% 459
2025
Q2 		$604 Hold
400
– – ﹤0.01% 493
2025
Q1 		$1.2K Sell
400
-500
-56% -$2.7K ﹤0.01% 417
2024
Q4 		$9.07K Sell
900
-400
-31% -$4.8K ﹤0.01% 325
2024
Q3 		$20.1K Buy
+1,300
New +$15.1K 0.01% 246

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Mark Sheptoff Financial Planning's ARTV Position: Q1 2026 in Review

Mark Sheptoff Financial Planning held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 400 shares worth $4.24K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Mark Sheptoff Financial Planning first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $20.1K in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Mark Sheptoff Financial Planning held 400 shares of Artiva Biotherapeutics worth $4.24K as of Q1 2026.
  • Mark Sheptoff Financial Planning left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Mark Sheptoff Financial Planning's portfolio in Q1 2026, its #450 holding.
  • Mark Sheptoff Financial Planning first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Mark Sheptoff Financial Planning's Artiva Biotherapeutics position peaked at $20.1K in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q1 2026, filed 11 May 2026.